JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on Cytokinetics and raises the price target from $65 to $71.
September 05, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has increased its price target for Cytokinetics from $65 to $71 while maintaining an Overweight rating, indicating a positive outlook on the stock.
The increase in price target from $65 to $71 by JP Morgan, along with maintaining an Overweight rating, suggests a positive sentiment towards Cytokinetics' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100